17
Participants
Start Date
September 30, 1999
Primary Completion Date
August 31, 2004
Study Completion Date
September 30, 2004
O6-benzylguanine
Patients receive O6-benzylguanine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
carmustine
Followed 1 hour later by carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
MetroHealth Medical Center, Cleveland
University of Chicago Cancer Research Center, Chicago
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland
National Cancer Institute (NCI)
NIH
Case Comprehensive Cancer Center
OTHER